Lunai Bioworks (NASDAQ:LNAI) said its subsidiary BioSymetrics has entered into a letter of intent with Geneial to explore a collaboration focused on rare neurological conditions.
The non-binding agreement aims to transform patient-generated information into structured datasets that can be used to support drug development and improve clinical trial recruitment. The initiative targets rare diseases, which the company notes affect around 300 million people worldwide.
Under the proposed partnership, BioSymetrics and Geneial plan to combine and standardize patient-driven datasets, identify relevant patient subgroups for clinical development, and build trial-ready cohorts that could be used in future pharmaceutical collaborations.
Initial work is expected to involve integrating data from multiple patient registries, including longitudinal clinical information to support research and cohort design.
“Geneial’s mission is to accelerate precision medicine by connecting patient communities, researchers, and industry partners,” said Adam Hansen, CEO of Geneial. “This collaboration connects our AI-enabled patient engagement and data platform with BioSymetrics’ capabilities to translate real-world data into targeted therapies and accelerate development timelines.”
Gabe Musso, Chief Scientific Officer at BioSymetrics, said the focus of the collaboration is to make data on rare neurological disorders more actionable for drug development programs.
The first phase is expected to concentrate on selected rare neurodevelopmental disorders. While both companies aim to pursue commercial partnerships stemming from this work, specific terms and project details will be defined in future agreements.
Lunai Bioworks is focused on AI-driven drug discovery, particularly in central nervous system conditions, while Geneial specializes in data infrastructure for rare and genetic diseases.
In separate developments, Lunai Bioworks recently agreed to acquire central nervous system assets and blood-brain barrier delivery technology from Clemann Group for $20 million, structured as Series B convertible preferred shares. The company has also temporarily furloughed staff in the U.S. and Canada as it seeks additional funding.
Lunai has also launched a collaboration with an undisclosed clinical-stage partner to analyze Phase 2 colorectal cancer trial data using artificial intelligence, aiming to identify patient groups most likely to benefit from treatment. Additionally, it introduced Sentinel, an AI safeguard designed to prevent the creation of novel chemical agents by advanced models.
The company is also advancing a drug discovery program targeting Alcohol Use Disorder, having identified key neurobehavioral patterns linked to alcohol exposure and withdrawal, as part of its broader push to expand its AI-driven pipeline.